-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 AMICHLvEGyYW9tpMb2pDUSwjQMqw3q6NNlE+a23XryZ4AbZmj3JL9urzQ23mEWOv
 7OaW5MDHhaTF7+Tij5MxtQ==

<SEC-DOCUMENT>0000950123-11-018650.txt : 20110225
<SEC-HEADER>0000950123-11-018650.hdr.sgml : 20110225
<ACCEPTANCE-DATETIME>20110225153842
ACCESSION NUMBER:		0000950123-11-018650
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110225
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110225
DATE AS OF CHANGE:		20110225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		11640752

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c13227e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="width: 7.5in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">
<DIV style="font-size: 10pt">
<DIV
style="border-bottom: black 2pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>
<DIV
style="border-bottom: black 1pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): February 25, 2011</B>

<P style="font-size: 24pt" align="center"><B>GEOVAX LABS, INC.<BR>
</B><FONT
style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="100%">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-52091</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>87-0455038</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="100%">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>1900 Lake Park
Drive<BR>
Suite 380<BR>
Smyrna, Georgia<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>30080</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(678) 384-7220</B>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="30%">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV
style="border-bottom: black 1pt solid; margin-top: 10pt; width: 100%; font-size: 1pt">&nbsp;</DIV>
<DIV
style="border-bottom: black 2pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="width: 7.5in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">

<P style="text-indent: 4%; font-size: 10pt" align="left">This Form 8-K and
other reports filed by GeoVax Labs, Inc. (the &#8220;registrant&#8221;) from
time to time with the Securities and Exchange Commission (collectively the
&#8220;Filings&#8221;) contain forward looking statements and information that
are based upon beliefs of, and information currently available to, the
registrant&#8217;s management as well as estimates and assumptions made by the
registrant&#8217;s management. When used in the Filings the words
&#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;,
&#8220;expect&#8221;, &#8220;future&#8221;, &#8220;intend&#8221;,
&#8220;plan&#8221; or the negative if these terms and similar expressions as
they relate to the registrant or the registrant&#8217;s management identify
forward looking statements. Such statements reflect the current view of the
registrant with respect to future events and are subject to risks,
uncertainties, assumptions and other factors relating to the registrant&#8217;s
industry, operations and results of operations and any businesses that may be
acquired by the registrant. Should one or more of these risks or uncertainties
materialize, or should the underlying assumptions prove incorrect, actual
results may differ significantly from those anticipated, believed, estimated,
expected, intended or planned.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;2.02 Results of Operations
and Financial Condition</B>

<P style="text-indent: 7%; font-size: 10pt" align="left">On February&nbsp;25,
2011 we issued a press release reporting our results of operations for the
quarter and year ended December&nbsp;31, 2010. A copy of the press release is
attached to this Current Report.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;9.01 Financial Statements
and Exhibits</B>

<P style="text-indent: 7%; font-size: 10pt" align="left">Exhibit&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Release

<P style="font-size: 10pt" align="left"><B>SIGNATURES</B>

<P style="text-indent: 7%; font-size: 10pt" align="left">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned
hereunto duly authorized.

<P style="font-size: 10pt" align="left">Dated: February&nbsp;25, 2011

<P style="margin-left: 46%; font-size: 10pt" align="left">GEOVAX LABS, INC.

<P style="margin-left: 46%; font-size: 10pt" align="left">By:<U> <B>/</B>s/
Mark W. Reynolds&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Mark W.
Reynolds<BR>
Chief Financial Officer<BR>


<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c13227exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><IMG src="c13227p1322701.jpg" alt="(GEOVAX LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax Labs Reports Fourth Quarter and<BR>
Year-End 2010 Financial Results</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>ATLANTA, GA, February&nbsp;25, 2011 &#151; </B>GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based
biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, today
announced its financial results for the fourth quarter and year ended December&nbsp;31, 2010.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax reported a net loss of $478,784 for the fourth quarter ended December&nbsp;31, 2010, as compared
to a net loss of $843,275 for the comparable period in 2009. For the full year of 2010, the Company
reported a net loss of $2,747,328 as compared to a net loss of $3,284,252 in 2009. Grant revenues
were $5,185,257 and $3,668,195 for the years ended December&nbsp;31, 2010 and 2009, respectively. As of
December&nbsp;31, 2010, the Company reported cash balances totaling $1,079,087. Summarized financial
information is attached. Further information concerning the Company&#146;s financial position and
results of operations are included in its Annual Report on Form 10-K, expected to be filed with the
Securities and Exchange Commission before March&nbsp;31, 2011.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Highlights of the Company&#146;s scientific and clinical progress during 2010 are as follows:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Early results from the Phase 2a trial for the preventative version of GeoVax&#146;s vaccine
indicated an excellent safety profile and highly reproducible immunogenicity. This trial
was expanded to include testing of an additional, simpler vaccine regimen, and we expect
patient enrollment and vaccinations to be completed during 2011.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">During 2010, GeoVax began recruiting and screening patients for a Phase 1/2 trial for
the therapeutic version of our vaccine. In order to accelerate enrollment in this
important study, a second site at the University of Alabama, Birmingham was recently added
to complement the enrollment already underway in Atlanta.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">We reported preclinical results using GM-CSF (granulocyte/macrophage colony-stimulating
factor) as an adjuvant, or immune system booster, with the DNA priming component of our
preventative vaccine. Results using GM-CSF showed protection from infection by a
genetically distinct simian immunodeficiency virus (SIV &#151; monkey version of the HIV virus)
in 70% of the animals tested. We believe this is the highest level for prevention of an
immunodeficiency virus infection ever reported in a nonhuman primate model. Based on the
results from this study, we now hope that our DNA/MVA vaccine supplemented with GM-CSF
could actually prevent, not just control, HIV infections in humans.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Robert T. McNally, Ph.D., president and chief executive officer, commented, &#147;During 2010 we made
solid, steady progress in developing our HIV/AIDS vaccines. For 2011, our goals include advancing
our Phase 1/2 therapeutic clinical program to the point of seeing crucial data from vaccinated
patients, completion of patient enrollment and vaccinations in the Phase 2a trial of our
preventative vaccine, and commencement of planning for the Phase 2b trial in the preventative
program. In addition we expect the HIV Vaccine Trials Network (HVTN)&nbsp;to initiate a Phase 1 trial
for the GM-CSF adjuvanted version of our preventative vaccine in the latter part of 2011.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Dr.&nbsp;McNally continued, &#147;We continue to benefit from tremendous financial, operational, and
technical support provided to us by the National Institutes of Health (NIH)&nbsp;and by the HVTN. The
HVTN, funded by the NIH, is the largest worldwide clinical trials network dedicated to development
and testing of promising HIV/AIDS vaccines. While we are deeply appreciative of the governmental
support we receive, it does not cover all of our activities, so fund-raising is also one of our
primary goals for 2011. We began the effort during 2010 and have laid the groundwork for success in 2011 through corporate capital restructuring, establishment of
investment banking relationships, and making numerous contacts among potential institutional
investors.&#148;
</DIV>
<P align="center" style="font-size: 10pt">MORE

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax Labs, Inc.<BR>
Add 1</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About GeoVax</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax Labs, Inc. is a biotechnology company developing human vaccines for diseases caused by HIV
(Human Immunodeficiency Virus &#151; that leads to AIDS). GeoVax&#146;s AIDS vaccine technology is
exclusively licensed from Emory University in Atlanta, GA, and is the subject of more than 20
issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected
people to prevent acquisition of HIV-1 and limit the progression to AIDS should a person become
infected. GeoVax HIV/AIDS vaccines also may be effective as a therapeutic treatment (for people
already infected with the HIV-1 virus).
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax&#146;s core AIDS vaccine technologies were developed by Dr.&nbsp;Harriet Robinson, Chief Scientific
Officer, through a collaboration of colleagues at Emory University&#146;s Vaccine Center, the National
Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC)&nbsp;and GeoVax.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax&#146;s AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine
Trials Network (HVTN)&nbsp;based in Seattle, Washington. The HVTN, funded through a cooperative
agreement with the NIH, is the largest worldwide clinical trials program dedicated to the
development and testing of AIDS vaccines. Preclinical work enabling evaluation of the GeoVax DNA
and MVA vaccines was funded and supported by the National Institute of Allergy and Infectious
Disease (NIAID), which provided additional support to the GeoVax vaccine development program with
an $19&nbsp;million Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD)&nbsp;grant awarded in
late 2007.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">For more information, please visit <U>www.geovax.com</U>.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About GeoVax&#146;s Technology</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax&#146;s unique two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara
(MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses.
Stimulation of both T cells and antibodies differentiates the GeoVax vaccine from many other
vaccine candidates. GeoVax&#146;s DNA and MVA vaccines are used in a prime/boost protocol in which
priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three
major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious
virus-like-particles. These particles contain proteins that mimic more than half of the components
of the HIV virus, but cannot cause AIDS. This multi-protein approach is designed to elicit a broad
multi-target protective T cell response. The Env protein is designed to elicit a protective
antibody response against the natural form of the virus envelope glycoprotein as well as protective
T cells. GeoVax&#146;s vaccines are unique in expressing virus like particles that display the trimeric
membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical
trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their
ability to raise anti-HIV humoral (antibody)&nbsp;and cellular (cytotoxic T cell) immune responses, as
well as the vaccines&#146; safety.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About HIV/AIDS</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">AIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation.
33&nbsp;million people are currently infected globally and it is estimated that there will be 2.5
million new infections this year. Since the beginning of the epidemic, over a million people in the
U.S. have contracted the virus. Every 9<FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">2</FONT> minutes, someone in the U.S. is infected with AIDS.
Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with
different subtypes (or clades) of the virus predominating in different regions of the world. Clade
B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B,
and C. GeoVax vaccines are currently designed t function against clade B. In 2008, antiretroviral
treatment in low and middle income countries was restricted to about 3&nbsp;million people. In the
United States, about 50% of those who are infected are estimated to be on drug treatment.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->MORE&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax Labs, Inc.<BR>
Add 2</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B><I>Forward-Looking Statements</I></B><BR>
<I>Certain statements in this document are &#147;forward-looking statements&#148; within the meaning of the
Private Securities Litigation Reform Act. These statements are based on management&#146;s current
expectations and are subject to uncertainty and changes in circumstances. Actual results may differ
materially from those included in these statements due to a variety of factors, including whether:
HVTN will commence, complete enrollment, and generate data regarding GeoVax vaccine clinical trials
as and when expected, GeoVax can develop and manufacture its vaccines with the desired
characteristics in a timely manner, GeoVax&#146;s vaccines will be safe for human use, GeoVax&#146;s vaccines
will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be
licensed and marketed, GeoVax raises required capital to complete vaccine development, there is
development of competitive products that may be more effective, less costly, or easier to use than
GeoVax&#146;s products, GeoVax will be able to enter into favorable manufacturing and distribution
agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to
update these forward-looking statements, and does not intend to do so. More information about these
factors is contained in GeoVax&#146;s filings with the Securities and Exchange Commission including
those set forth at &#147;Risk Factors&#148; in GeoVax&#146;s </I><I>Form 10-K</I><I>.</I>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>FINANCIAL TABLES FOLLOW</B>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->MORE&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS, INC.<BR>
Statements of Operations Data</B><BR>
<I>(amounts in thousands, except per share data)</I>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">Three Months Ended</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">Year Ended</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000">December 31,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000">December 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Grant Revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">946</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">397</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,185</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,668</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">774</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">538</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,794</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,068</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">654</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">711</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,162</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,915</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,428</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,249</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,956</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,983</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss from operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(482</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(852</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,771</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,315</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(479</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(843</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(2,747</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(3,284</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.03</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.05</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.18</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.22</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted averages shares outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,655</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,608</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,651</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,191</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Balance Sheet Data</B><BR>
<I>(amounts in thousands)</I>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000">December 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,079</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,516</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Working capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,081</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,309</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,358</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,316</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deficit accumulated during the development stage</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(20,285</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(17,538</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,836</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,744</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt">* * * * * * * * * * * * * * *
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->###&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>







</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c13227p1322701.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c13227p1322701.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`$L`S@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`/#/CK
M^T+X`_9YT+2=<\<+K=V=<U"33])TCPY9V5[J]X]O$LMY<1Q:AJ-A;I:6R2P>
M;))<H0;F)55F?%>[D7#V8<0UZU#`>SA]7@IU)UI2A3BI.T5>$)R<I._*E%[-
MNR1X>>\0Y?P]0HU\=[27MYN%.G1C&523BKR=ISIQ48JW,W);I*[9Z!\/O&:?
M$#PEHWC"#P[XD\+V6NVD6H:=IOBN#2K366T^Y19K.]GM-(U?48[:.X@=)4CE
MG68*X,D:$XKS\PP3R[%UL&\31Q,Z$G"<Z#J2I\Z=I14JE.DVXNZ;4>6^S9WY
M?C%C\)1QD<-6PL*\5.$*ZA&IR25XR<:=2HHJ2=TG)2MND=G7$=H4`%`!0`4`
M%`!0`4`%`!0`4`9VIZOI.B6KWVLZGIVD64?,EYJ=[;:?:I@9.^XNI8XUX]6%
M:4J-6M)4Z-*=6;VC"+E+Y**;_`SJU:5"#G6JPHP6\IR4(KYR:1\\>*_VP_V;
M_!WFIJ'Q2T+4;B$LAM?#*7OB>1G7K&LVA6MS;JV>/GF0>IKZ+"<'<28Q1=+*
MJM*#^U6Y:"^ZK*,ON3/G<7QAPW@N:-3-:52<?LT>:L__`"DI1^]H^=_$?_!3
M/X,Z:[1>'?"GCGQ&ZYVS2V^DZ)9.>VV2;4;BY`/^U:`^U?18;PRSF=OK.+PN
M%792G5DOE""C]TCY[$^)F34KK#8/%8EKJXPI1^^4W+_R4\8U3_@I_P")[VX-
MMX2^#FFQ/(<6PU3Q#J&KSR'.!FTT[2K`^G"RMUZU[5+PNPM**EC,YG;KR484
MU_X%4J2^^QXM7Q0Q4Y<N"R:%^BG6G4?_`(#3IQ_,JP?M;?MR>,Y/^*1^#:VM
MN_\`JY=-^&OBR[B4-]TF_P!5OY[<\=R`*M\(\"X'3&9US-;J>,H1?_@-*',1
M'BWCG&_[EDO(GLX8.O)?^!5)\IJQZY_P4\\3D"UTNXT"%_XI-,^&.BA`WJ-7
M'VA2/IFLI8?POPF]55VNT\;5_P#2%&/Z&T:_B?BOAI?5UYPP=+_TMRE^IHQ_
M"S_@I1JHS>?$NWTLMU$OBC0K3;GK_P`B_I4H'_`1]*S_`+5\,Z"]S*W6M_TX
MJO\`].5H_D4LJ\2ZOQYG&@O^O])?^FZ+_!E^+]F[]OV]`-]^T1:6.<96+Q[X
MRW+Z_+9^'$7\FK-\2^']/^'PTYV_ZAJ"_P#2JS9K'AKC^7Q\2*G_`-S-?_VV
MBD75_9/_`&U'P9_VI+B,]Q%XU^(3`=_^?&//-1_K9P0M(\**WG0PJ_\`;F6N
M$^-NO%;7I7Q7_P`BBQ'^RA^V?%]S]JF\R,D;O%OCYASZ[[8\5+XLX)_Z)*/_
M`()PJ_)HI<)\;+;BQ_\`@[$_Y$__``S7^W39C-G^TY:7!'W5NO$OB]@<=CY^
M@3#^=+_6;@.7Q\*N/^&E1_\`;:L1_P"K/'</@XJ3]:E;]:4B(_"'_@HWI+!K
M#XW^%=2"]%DU.&X+`=`5UGP)@GZM^-']L>'%7X\BKT/\,&O_`$C%!_8_B-0_
MAY[0K6[R3_\`2\*61'_P4ST),^;X+\5+&/NG_A7\;28]"8]*=C^*TK^%];2V
M+PE_^PG3\:R';Q/PZWPF)4>G^S:_A19\T?$K4_%G[1_[2WA/P1XG@/B:'X2^
M&]GCC3_"=FTUMJ.H^%[(Z_\`$:TT.R@DE9IKW78AX:MF1W\V2WLG'^L`KZ/+
M:6$X:X9Q>.PK^J/-JU\+*O))PA7E[+!RJR:C94Z3>)G=*R<ET/G,RJ8OB/B7
M"8'%+ZS'*:-L3&A%VG.A'VN,C2BG+6=5+#0LWS-1[GTE#^WYX^\*C[-\1/V8
MO%WANWM0(O.MIM8TR*"*,!56.SUGPM"FQ4&`%N0O`Z=OG'X?9?B_>RWBG#8A
MO6TE3DVWK>].M)ZO^Y<^C7'^/P=HYCPOB<,HZ>[SQ44NEJE&*T7]Y'H/AK_@
MI!\`=7"+K=IXW\(RY"R-J6AP:C:(<X)670]0NYW4'K_HJGVKS\3X:\0T$W0E
MAL7%;<E5PD_E5C!?=)GH8;Q)X?JM1K1Q.$EUYZ2G%?.E*;_\E1](>$OVE/@-
MXV:*+PY\5?!\]S,`8K'4-330M0?=T5-/UU;.X=\G&U8R:^:QG#.?X!-XG*<1
M"*^U&FZD/_`J7/&WS/I,'Q+D.-:6%S7#RD]HRJ*E/_P"IR2O\CVR*6*:-)H)
M(Y89%#QRQ.LD;HW(9'0E64CH02*\1IQ;BTXM;IJS7R/;332<6FGLUM\FB2D,
M*`"@`H`*`(YIHK>*6>>6."""-YIIIG6**&*)2\DLLCD+'&B*69F(``))P*:3
MDU&*<I2:225VV]$DENWT0FU%.4FHQBKMO1)+=MO9(^&OB_\`M_?!;X:R7.D^
M&IKCXE^(K=GB:W\-S10^'K:9=X*W?B697AE`=0,Z=#?C)PQ4BON<G\/\ZS%0
MJXE1RO#2U3K)NJT^L:"M)7_Z>.G\SX;-^/\`)<M<Z.%<LSQ,=.6BTJ47VE6?
MNO\`[AJ?R/SE^(?_``4'^/WC62:U\.7NF?#S2Y6VQVOABR6?53&>`LVMZH+B
M?S<G_66:67;"BOT;+O#[A_!*,J].IF56.KE7ERT_/]U3Y5;_`!RF?G68^('$
M&-O'#U*>6TI:*-"-ZGE^]J<SO_@C`Y;PI^S7^U3^T#<0ZYJ6G^)Y[*Z)F3Q3
M\2]9O[*U*2/M,UK_`&P\NH7D#98J]E:3H0.#C%=>*XEX6X=BZ%*K0A4IZ>PP
M-*$I)KI)TU&G%_XZB9RX7AKBGB"2KU*5>5.6OM\;4G&-GUBJEYR7^"%C[*\"
M_P#!+W1X!%<?$GXDWU])N1I=+\&Z=%8PK@`M&-9UE;AYE)R,C38#CIS7QF/\
M4*KYHY9ED::Z5,3-SEZ^SI\L5_X'(^RP/A?1BHRS+,Y2:WIX:"IQ_P#!E3FE
M_P"21/5/$GPD_8/_`&:X(6\=:7H$^KO&MQ!I_B6]U;QEXAOD7`29?#,,DT,=
MNS<"9K""`D$;^#CR\-F_'O$DI+`5:L:*=I2H1IX:C#R=:T7==O:2DNQZF)RC
M@/AF,7CJ5)UK7C&O*>)K2\U13DK>?)&/F4-&_;O_`&2/"G^C>&/"6N:';Q#9
M&V@>`/#^DP,J\#8EKJD#@8_O(IK2MP%Q=BO>Q.+HUY/?VN,J3?WN,E]S,Z/'
MG".$]W"X2M0BMO98.G37W1E%_>CTSP3^WI\`O'7BK0O"&G77BK3-3\1:E:Z1
MID^M:%#:Z>^HWTJV]C:RW%IJ5RT#3W4D4*.T80/*N]E7+#S,=P#Q!@,)7QE2
M.'J4L-!U)JE6YIJ$5>4E%QC?E5VTG>R=DST\#Q[D&.Q=#!TI8BE5Q$U3@ZE'
MEASR=HQ<E*5N9V2;5KM7:/M&OBC[0*`"@`H`Y;QKXIC\$^%]8\53Z-K>NVFA
M6<NHWNG>'+6WO=9:QMD,MW-965S=VPO'AA5Y#"DGF,J-Y:NV%/5@L*\;BJ.$
MC6I8>5>2A&=:3C34I:14I1C+E4GI=JR;U:6IRXW%+`X6MBG1J5X4(N<H48J5
M3E6LG&+E'FLM;)W:V3>AYW\$OV@/AY\?M(U?5O`5QJ8_L&]@LM6TW6K*.PU.
MS>ZB>:SG>&&ZN(GM;A8K@1R),V6MI58*4Q7I9YP]F/#U:C1Q\8?OXN5.=*?/
M"7*[25[1:E%M732T:>J9YV1\09=G]&M6R^4_]GDHU(5(<DX\RO%V3DG&23LT
MWJFG9H]MKPSVSQOX_P#Q/M_@[\(O&OCQWC6^TO29;?089",7/B+4R+#1(=F"
M9$%_<0S2@`D0P3-T4D>SP_E<LXS?!8!)^SJU$ZK7V:,/?JOR]Q-+^\TNIX^?
MYG')LHQN/;7/2IM4D^M:?N4E_P"!M-_W4V?%?_!-KX87%AX3\6_&C74DEUGQ
MYJ4^D:-=W.7N'T33+MI=7OA(PW-]O\0;XW))R=$5OX^?M?$G-(SQ>$R7#M1H
MX""J5(QT2J3BE3A9;>SHVM_U\9\5X;Y7*GA,7G-=-UL?-TZ<I;^SA)NI._\`
MT\JWOW]FGU/TW(!!4@$$8((R"#U!'<5^8^A^FGGGB7X1?"SQBDB>*/AUX*UT
MR9+3:CX:TF>Z!/5DO&M//B?_`&DD4^]>CALWS3!-/"9CB</R[*%:I&/_`("I
M<K^:/.Q.497C$UBLNPU>^[G1IM_^!<O,ODSYK\8?\$__`-G'Q.)I-.\/ZUX+
MO)5.+CPMKUXD2/SAQ8:U_:-J@R>5BBB!''%?38/Q!XEPEE/$T\9!=*]*+=O\
M=/V<_FVV?-8SP^X:Q5_9X:I@I='0JR23_P`%3VD/DHH\'N/V'OCM\+9'O_V?
M_C_J=M%"-\'A_6;C4M`BDP<F*3[#+?Z9J+D8(%S86\>1R0#7O1XYR'-$J?$'
M#M-MZ.K2C"HUY^\J=6/_`&[5DSP9<#Y]E3=3A_B&I%1U5*K*=)/R]UU*4O\`
MMZE%&?\`\-5?M9?`.:*T_:"^$O\`PDV@1R+"WBO3;:/3&D52$,JZ_H"7>A3R
M,"K+;O;6LK9^9ER<:?ZI\(Y]%RX=S?ZIB&KK#U&YV\G2J<E=+SC*HEV9G_K7
MQ;P_)0XAR?ZSAT[.O32A]U6EST'Z2C3;\C[,^#?[6/P8^-?V:Q\-^(AH_B>9
M5SX0\3+%I.N-*54M%8`S26NL$,3Q8W$[X7<Z)TKXO.>$LZR/FGB<-[7"Q_YB
M*%YTDO[^BE3_`.XD8KHFS[/)N+,ESKEIX7$^QQ3_`.8>M:G5O_<U<:G_`'#E
M)]6D?2E?-'TH4`87B?Q)H_@WPYKGBKQ!=K8:)X=TN]UC5+I@6\BRL('N)V2-
M?FEE*(52-<L[LJ*"S`'?"X:MC,30PF&@YU\3.-.G%=93:2]%=ZO9*[>AABL3
M1P6&KXO$35.AAH2J3D_LQ@FW\[+1;MZ+4_G\_:@_;!\9_'+5[_0="O+WPW\+
MK6YEBT[0+:1K:YUZ&-RL>I>)Y(F!NY90HD2Q+&WM\J`LDJ-/)_0'#'"&"R"C
M3KUH1Q.:R2<ZK5XT6UK3H)Z14=G4MSS>J<8VB?@'$_%V-SVM4H4)RPN51;4*
M,7RRJKI.NUK+FW5._)%;IRNSQ;X(?`WQO\>O&$?A3P=:HL<"QW6O:]>^8FD^
M'M->38;R_E12SRN0ZP6T8,L[J0H")))%[.=YY@<AP;Q>-D[R;C2I1M[2M.U^
M6*>R6\IOW8K>[:3\?),CQN>XM83!045%*56K*ZIT8-VYI-=7M&"]Z3VLDVOW
M>^!W['OP@^"5M:7EKH\/BWQC$JO/XO\`$EK!=74=P.6;1=/</;:'$&)"&$/<
M;>)+F3K7X5GG&.<9U*=.59X/!-Z8>BW&-O\`IY-6E5??F]WM!'[ID?!^3Y)&
M$X45B\;'?$5DI23_`.G<-8TEVY5S=YL^JZ^4/JCY:_:W^/W_``H#X7RZQI0@
MF\:>)+E]"\'V]P@DB@O6@:6]UJX@((FMM.MBL@C8%7N)[2)QLE8CZGA'A_\`
MM_-(T:MXX+#)5<0XZ-QO:-.+Z2JRTONHJ4EJD?+<6Y__`*OY6ZU*SQN)DZ6'
M3U2E:\JDEUC2CK;9R<8O1L^-_P!F_P#8H7XFV4/QI_:-O]<\0ZEXR9=?T[PS
M<ZA=VUS>VMZ4GMM8\4:C'(MXS7<'ER06-O+;^7`\7FN=_P!GA^SXDXV_LN;R
M3ANG2PU+!?NI5HPBXPE'25.A!IP7(])5)*3E).R^T_C>&^"5F4%G7$=2KB*N
M,_>PH2G*,I1EJJE>::F^=.\:<7%1BU?^5?=\7[*_[.D$:1)\&_`A6-0JM-HD
M%Q*0.A>>X+R2-_M.S$]S7P<N*N(VW)YSBKOM5:7W*R7R1]W'A7AR*45DN%M'
M:])-_>[O[V"_LM_`"WN=/OM-^%WA;1=3TG5-,UG3-4T:Q&G:A9:CI%_;ZE8S
MPW%NRG:MU;1%HV#(ZY5U(-'^M/$#C4IU<TKUJ56$Z<Z=2?/"4*D7"2:?DW9[
MIV:=QKA;A^,J=2EE5"A5HSA4A.G#DG"=.2G%IJW5*ZV:NFCWZOGSWR`7-MYW
MV<7$'V@#/D"6/S@.N?*W;L?A5<DDN;E:CWL[??L3S1OR\RYNUU?[B>I*"@"N
MD]K<&2**:WG*Y66-)(Y"H/!61%)QGD8(JG&4+-Q<>SLU]Q*E%W2:=MTFM/5'
MX]^`%/[)O[<>J^")3]@^'?Q8D2UTG>1'9Q6/B6Z>[\+.FX*N=-\1I<:+O)^6
M*2X<_?Y_8<?_`,99P-2QL??S'*5S5+?%S48J-?;7][1Y:UNLDD?D&7K_`%3X
MXJX%_N\NS;2GTBHUI.5#LOW=92HWZ1;?4_8ROQP_83\D?^"@GB_5?B)\1OA?
M^S9X0<SWUUJ>FZKK$$9<QG7?$$ATSP];W80_(EGID][>R[A@1:I%(<;,C];\
M/L'2RW+<TXEQBY:<(3A3;T?LJ2YZSC_CFH4UW<6NI^2^(&+JYAF.5\-8-WJ2
MG"=1+_G[5?)14O\`!!SJ/RDGT/TZ\'^'/#WPQ\$^&/!]C/:Z?HOA?1M/T2SE
MNI8;59A96Z1/<RO(ZJ;FYF$D\ASEI)G;J:_,<9B<1F>-Q6,G&4ZV)J3JR44W
M;F;=E;6T5:*[)(_3<'AL/E>"PN#IN-.AA:<*47)J-^56N[Z7D[R?=MG23ZMI
M5I#!<7.IZ?;6]R<6T\][;0PSG!;$$LD@64[03A2>!7-&C5DY1C2G*4=THMM>
MJ2NCIE5I0C&4JL(QE\+<DD_1MV?R([K6]%L'CCO=7TRRDEC$L4=U?VEN\D1Z
M2QK+*I>,Y'S`$<]:<*%::;IT9R479N,)-)]G9:/R%*M1IM*=6%-M72E*,;KN
MKM:&A%+%-''-!)'+#(JO%+$ZR1NC#*O&Z$JRD<@@D&LVG%N+3BXZ--6:?FNA
MHFFDXM.+U36UO)HKWFHZ?IRH^H7UG8)(Q6-[RZ@M5=@,E4:=U#,!S@9JH4ZD
MVU3IRFUNHQ;M]R)G4ITDG4G&FGMS24?S:&))IFLV4@CDL-6TZY22"4(UO?65
MPARDL,@4O%*A&59#D=B*;56A-74J-2-FMX23W36S7DQ)TJT'9QJTY73M:46M
MFGNGYH^$/CQ^P/\`#OQ_%=>(OA>EM\,_'<;&[MTTY)(/"FIW:.9E6ZTRV_Y`
MLS28VW6G*BQM\[VTS<C[S(>/\QRYPPV9MYG@'[KYVG7A'9\LY?Q%;>%6]]E*
M)\)GW`.78]3Q.5I97CU[RY$U0G+=<T(_PFWM.E:V[C(XK]DO]H+XC:#X_O\`
M]F;]H(WR^,M-#6_@_6-5VRWUTUE;3WDND:CJ@D(U>*XTY([K3M0)D,R1O&\T
MIFMPO;Q;P]EM?+Z?$_#JC]2J:XBG3TA'FDHJI"GO3<9ODKT]%&34DDN8XN$N
M(,QP^85.&.(>98VGIAZE36<N5.3ISGM44H>_1J:N45*+;?*?IG7YD?IA\]_M
M6>#-=\?_`+/?Q/\`"OAE9I-;O-$M+^QMK8,;F^_L#6M,\0W&FVR(09+B]M-*
MGM$C'WWN53G=BOH>%,;0R[B'*\5B6HT*=5QE)[0]K3G24WV4)5%-OHHW/GN*
M\%7Q_#V:87"IRKRI*48K>?LJD*K@N[J1@X)=7*W4_F;N+:XL[B>TNH);:YMI
MI+>XMYXWAGMYX7:.:&:&15>*5)%961@"I4@@$5_2T7&48RA)2A))Q:=TTU=-
M-:--.Z?5'\UN,H2E&47"46U*+5G%IV::Z-/1KHS]\?\`@G)HV@6'[/,6JZ7'
M!_;&M^+-??Q)<(%-Q]KT^:.STZSG<?,(XM)%I/'$3A3J$C@9F8M^"^(U;$3X
MA=*JVJ-"A25&/3EFG*<DMKRJ<R;Z\J3V/WGPZHX>GP\JM)+VU>O5=9]>:#Y8
M1;[1I\K2_O-]3[WKX(^\"@#\@_\`@H:HUCXY?L_^&=69O^$=N(+5;A'8K`%U
MKQ=;6&L.><!OL-G:;CUP!7Z_X>?N,BX@Q-%?[3!NS6_[O#SG3_\`)I2:\S\A
M\0OWN>\/X6J[8>2C==/WF(A"?_DL4GY'ZV7MS;:+I5W>&+99Z3I\]R8+=%79
M;6%L\IBAC^55Q%%M5>`,`<"OR2$95JL(7]^K-1N^\G:[>^[U/UJ<HT*4YVM"
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MBY052"3LW?L]KH[#]JCXX_%/QO\`%JP_9;^`5W<:;K=PL,'B[7]/N9+&\6>[
ML1J4]@FKP@R:/H^GZ0ZW-[=08G=G:!,>2T5UP\*Y'E6`RBIQ3G\%4H1N\/1F
MN:-HRY%/V;TJ5*E3W:4)>ZDN=[IQ[N*L\S7&YM3X6R";I5Y66(JPERRO*/.X
M<ZUITZ=-\U64?>;?(MFI<W_P[/UE--&JQ?'"^7QZ%^U?;/["NETW[?\`?V#4
M5UO[>J[^/M?EE_X_(S\E=7_$3:'M?9/(:?U"]N7VD>?D_P`'LO97M]G;IS=3
ME_XAG65+VJSVHL>E?F]G)0Y_\?M?:VO]K?KR]#J_V3OCC\4O"OQ7U?\`9<^/
M%W/J7B+38[E/"NN7]RU[?O+I]B-3&G2:I+B36=+O=#5K^RNY\SJL7E.6$R1V
MW'Q9D>58K*:/%.0P5'#5''V]*"Y8)3ER<Z@M*<X5?W=6$?=NU)6LW+LX3SO-
M<)FM;A?/9.IB*2E["K)\TKPCS\CF[.I"=/\`>4IOWK+E=[I1\Z^(7Q"^,O[8
MOQG\0_!WX/>()O!_PN\'S75KKNN6UQ<V=OJ-O97?V*ZUK6;FR*W%_#=7L<L6
MG:3$ZQS1H)I@")9;;TLNR[)>#,FP^<9QAEB\UQBC*E2<8R<'*/-&G3C).$'&
M#4JU:2;BWRQZ*7FYCF&<\8YSB,FR?$/!Y5@W*-6K%RBIJ,N652I*%I24IIJC
M1BTI)<TNKC>U[_@G9XZ\"Z6WBGX0?&/5KCQUI,1O8K1K2?PO+J=Q`OG&'3=8
ML-:F:SN9'4B-+E6B=F59)HU)81A_$7`8VJL)F^24H8"J^5R35903TO.G.FE*
M*ZN#4DM8IO0O$>'6/P-+ZUD^=598ZBN91:=!S:UM"I"HW&3>RFG%O232U/GC
MQ_XY\2?M%_!2YU_Q-"\/QL_9LU.V&O:A%;_8-1U_P)K%ZFFW&IW-M"L9@UK1
M/$=K8_:O+1$C2ZDN`J/-*$^AR_`X;AO.X8?"N^2<2P?LH-\T*6*IQYU"+=[T
MZ]&4N2[;>D6VHJ_SV/QV)XBR25?%1Y<[X:G'VLTN2=7"U)<CG**M:I0K1CSV
M22NY)+F9^N7P3^.&C^//V?\`1/BYK5[%;II?AF]G\;RY"BQU;PO:R+XBD9#C
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M6-*MO$Z-J7AW2?LIU/4'TRXPUG>PV4MU;V'AS2I8OWEM:V\+EXF20I$)`7\?
M,>+LHX5JRR?(LJI5985\E:;ER04U\47.*=2M43TG.4DE*Z5['L9=PCFW%%*.
M;YYFM6C'%+GHP4>>?(]8R4&U3HTY+6$(Q;<;-VNCQ3]IC]F_XH_LV^&#96?C
M.\\8?![Q-J-K;3!H'MXM*URV9[W3UU#1IY[J'3KV1()Q#J5E*K2JL]O(8UF\
MJ?VN&N),KXDQ*G+`QP6<X2$I*S3<Z3]V?)42C*<5=<U*HGROEG&]KKQN).&\
MTX:PSA'&RQF3XJ<8NZ:4*J?-#GIMRC"3L^6I3:YES0E:]G^@'P:^#_A7]H#]
MC+X<^&O'4'VN^;0M9BT'Q-(BSZWX;O;/Q!K=KI=WIUW)^\$%O%%!"UH9!%-;
MQ^0XV8*_G^<YQB^'N-,RQ6`?LX*K3=6@O=I5HRI4Y3C.*TO)MM2MS1D^9:[_
M`'^39/A,_P"#,MPN.CS3]E-4JSUJT91JU(PE"3UM%))QORRBN5Z;?/?[-GQQ
MUS]E?QSXD_9S^/MVVE^&-+FO;SPUXAN1<366COY4E[&;.01L]QX8UJW436WE
MJ3!=RE&16N+C[/\`0\2Y%0XIP.&XCX?A[3$U5&-:C&RE45U%\RT2KT'[L[_'
M37,F^6/-\]PUGE?A7'8GAS/Y^RPM)RE1K.[C3T<ERO5NA72YH6^"HW&RYI<N
M#X-T3Q%^WS^T#J'C;Q/#?Z=\$/`%PEM::6TDL4<EA'(TNG^'H'B8*-;U8J+S
M4[B%B\,#>4LBXLC71C*^'\/^'Z>!PDH3SS'IRE-)-J;5IUG=?PZ/P4(M6E.\
MFOC,,'0Q''W$%3&XJ,Z>1Y>U&-.[2<4[PHJW_+RM\=>2UC"T4U[A^R.DZ1I>
M@Z=9Z/HFG66DZ5IT$=K8:=IUM#9V5I;Q*$CAM[:!%CBC50``JBOQJK5JUZDZ
MU:I*K5J-RE.;<I2;W;;U;9^QTJ-+#TX4:%.-&E32C&$(J,8I;)15DD:-9FA\
M$?M&_#B7QC^U)^RC?>&;:./7M'U/6_$_C#4K88GMO!O@G6O">L:>-4:-@T5E
M<7=QK6GV[.-LD^IM$,\@??<-YBL%PKQ;#$R_V>M"E0P\'M+$XFGB*<E!=7&,
M:=6=OA5--VNCX'B/+GB^*N$YX6%J]&=6MB)Q^SAL-4H5(N;6RE*52E"_Q.I)
M*]G;[WKX$^^"@#X'_:=_8:\+_&:ZOO&O@BZM/!OQ%G5I;[S(F'ASQ3<`<2ZM
M%;HTFG:H_1M0MXY/,ZSP2N?-3[[ACCG%9+"&!QT)8S+8Z0L_WV'7:FWI.FO^
M?<FK?8E%:/X+B?@?"YS.>.P,XX+,9:SNOW-=]ZB6L)O_`)^13O\`:C)ZGPO\
M'_&WQI_84\9WVC?$OP-KC?#OQ'=Q+K,$*+<:;+<PDPP>(/"NM1,UA/J2VXVR
M6S3H;B$1QSB&2.*2#[K-\!DG'6"A5RO'4O[1PT7[)OW9J+U=&O2?[Q0;UC-1
MER2NTY1<D_A<HQV=<"8V=+,\!5678B2]JE[T&UHJU"JOW;FEI*#<>>-DU&2B
MU^SWPW^*O@#XLZ##XB\`>)=/U^P9(S<102>5J.F32('^R:MIDVVYTVZ&2-D\
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MM1DTG5LK.K33^.$UK)*[@VTU:S?V#'''#&D42)%%$BQQ11JJ1QQHH5$1%`"(
MJ@`*````!7Q[;;;;NWJV][]V?7I)))*R6B2T22V21^1'_!17(^,?[/W7`BEQ
M]?\`A)],S^/2OU[PY_Y$W$'K_P"Z]4_(_$7_`)''#_\`7_,12$\&ZYIGP@_X
M*)?$/_A/I8=*M?':ZO:>']9U%A#91/XK;1]9T2474I"1P3?9)-*$A(59Y/+8
MJ%?"QE"KF_AUEO\`9Z=66`Y'5IP5Y/V'M*=5<JU;CSJK;=Q]Y7#!5Z63^(F8
M_7VJ,<?[14JD](KV_LZE)\ST2ER.E?92T=M3Z4_:>\*_M4^.O&^B:-\"?$DO
MA'PKI'A>'4=8U(:T?#L6H:]J6J:E;BS^VV\,MU?/!I^GV\GDHODQ"X+.=\R`
M_-\+XOA3`8&O6S["K%XNM7<*4/9>U<*4(0;ERN48QYIS:N[RE:RTBSZ/BC"<
M58['4*.0XIX+"T:"G4G[3V*G5G.:4>91E*7+""=E[L;W>LD>$_!_]D3]HVU^
M//A3XM?&#Q?HNJGP[Y\USJC>(;_7M=O1%I5YINGV$/FZ?%A%-V,O+,H2.-@`
MQ(4^]G'%_#;R'%Y1DV#J45B+*--4HTJ4+U(SG-^_)W?+LEJVMD>'D_"/$<,^
MPF;9QC*57ZM=RJ>UE5JSM3E"$%[D59<V[>B3W9B_\$\O$.E?#WXB_&7X/>+G
MBT?QQ>ZQ:+8)?$6\VJ7/A:ZURQU;2X'FVF6Z0WB7442DM+$;B1`5B)K7Q#P]
M7'Y;DN<8-.K@:=.7,X:J"KQISIS=MHOE<)/I))/5F/A[B*679CG.3XMJCCIU
M5R*6CFZ$JD:D%?>2YE-+=Q<FKV/UFU;5]+T#3+_6M:O[32M(TNUFOM1U&^GC
MMK.RM+=#)-<7$\K!8XT0$DD^W4U^34:-6O5IT*%.52K4DHPA%-RE)Z))+5MG
MZQ5JTL/2J5JU2-&C2BY3G)J,8Q6K;;T21^1?['^DZ=\8OVA_VF_&D&F2-\-O
M%NC^,=$NX)(6A@O;7QYXGBN[*WD5E"I=2Z7IM_.Z8+1M)SC<,_KO&%6IDW#O
M#&!=1+,L'4H5(M.[C+"T7&37DJDXQ3V=C\CX/I4\XXAXGQL:3_LW%TZ].2:L
MI1Q592C%]G*G"4FMU<^1_$OB_P`>_`/1/CE^RPRSRVFO>,-+C6\5GCG6QLIC
M+)<6=NB'?'XBTE/#C.!M_<P[,'S6`^NPV#P&?5\BXI5HSP^'F^72W/)6M)]'
MAJCK6\VGT/DL3B\?D%#/>%K-PKXB"YM4^2+NW%?]1-/V-_)-=3ZA_:1^`>I_
M"[]B_P"$^FV]FWVSPYXLM?$_Q#$:DM#K/B[2KJWEN+DJ`&6PNGTW1ED(&0(?
M[QS\OPUG]+,^-<UJRG:&(H.CA+]:>'G&24?.I%3K6[\Q]/Q)D%7*N"\JI1C[
M^&KJMB[=*N(A*+<O*$G"E?M8_3CX`^/O#'Q&^$?@77_"MU:R6D?AS1]+OK""
M2,RZ)JNF:=;6=_H]W`AS;36\\3*H8*'B,4J9CE1F_,<_R_%99F^.P^*@XS]M
M4G&33M4A.;E"I%_:4D[W6SNGJFC].R#'X7,<HP.(PDXN"HTX2BFKTIPBHSIR
M7V7%JUGNK26C1\R_\%%/'WAC0?@3>^"+ZZM)?%'C75=$&B:5O1KV&TT?5K75
M=0UIH0=T-G&ED+3S2`&DOU1<X?9]-X=Y?BJ^>PQU.$HX7`PJ>TG9J+E4IRA"
ME?9R;ES6Z*+;Z7^9\0\?A</D4\#.47BL;.G[*%_>4:=2,YU+=(I1Y;]92276
MWJO[$O\`R:_\*O\`L':Y_P"I5KM>5QM_R5&;?XZ?_IBD>KP5_P`DOE/^"I_Z
M>J'Y]?ME^(#^TM\<?#_P@^#WABS\3^(O!-MK%AJ7B6S,27%]>0J;O4])_M%Y
M$MX]"TEX)4\V=]K7UW<1Q$;E-U^@\&8;_5G(L1G&<8J6$PV-E3E"C*]H1?NT
MZG(ES>UK7TC'54HJ4O[OY]QEB/\`67/,/D^3X6.)Q.!52,ZT;)RDES5*?/\`
M"J5&VK>CJR:C_>^@/^">_P`9]!F\+W/P"UC1[/PEX[\&76K7,%K]G-A/XHA^
MUROJLUY#-B0^)].F!@N8G`=K:W@=%Q;3B'Y_Q"R7$1Q4<_H5I8O`8R--.5^9
M4'RKV:BUHJ%1>]3>RFY)N\HW^@\/LYP_U6605J,<'C\%*I)1MR.LN9NHY)Z^
MWIOW:BW<5%I6C*WZ6DA068A54$DD@``#)))Z`"OS0_2C'U2ZU06P70+6UN[R
MX4^1<WLYBTJU!'RW-TT&Z:Y0$@B"W7=)C:9(@?,7:E"ES?OY2IPCO&*]]^4;
MVC'_`!2T6]I;&-657EMAX1E.6SD[0CYRMJ_\,=7M>.YSGA#P'9^%[[6_$%W?
MW7B#QAXG^Q#Q#XEOU6*:YMM-^T_V7I&F6,3&'1?#]B;R\-M8P%L-=SS3RW%S
M/+/)TXO'3Q,*&'A3CAL'A>;V-&&JBYVYZDY.TJE6IRQYZDND8QBHPC&*Y\'@
M(86=:O*I*OC,3R^UK2T;4+\E.$5[M.E#FER4X]92E)RG*4GWE<!W!0`4`4M0
MTW3]6LY].U6PLM3T^Z0Q75AJ%K!>V=Q&W6.>UN4>.9#_`'74BKIU*E&<:E*<
MJ52#O&4).,HONG%II^C(J4Z=6$J=6G&I3DK.,XJ46NSBTTUZH^7M;_8Z^$LF
ML?\`"4?#]O$OP<\6)\T.N?#/6Y]#CW"02^7/HLRW&GM9NPVR6\-O;K(ORM7U
M5#C+-XT/JF8*CG.#ZT<;256R_NU5RU8R[2YFT?+5^#<H]M];R[VV2XQ7M5P5
M1TE?^]2?-2E'O'E29U&DZ;^TAX+"V]SKO@/XS:1`,)-JEI=?#7QLT8&%62ZT
MR'5="U*8*!EFM-,WG)9QNXXZM3AS&^]##XK):TND)1QF&3\HS=*O!>7/5MT3
M.NC2XCP5HRKX7.:,=G.,L'B;><H*K0F_^W*5^K1Z'8>/)G7R/$O@KQAX6G\O
M]_\`:=,A\0:7D\,(]4\*7.IPF(YP&N%MSS\R+TKSJF`BM<+C</B8WTY9NE/Y
MPKQI._\`A<O)L]&GCG\.)P6(PLK:W@JL/E.@ZBM_B4?-(^(_BW^P5\-OB1J]
MQXQ^$?BI/ASXCN;@WT^G6<)N_#DM[O$CW%K8V]Q;W?AZ9I,L?LS20HW^KMD.
M<_<91Q]F6648X+-\)_:6&BE%3D^6LH;*,I-2A626BYUS=YL^'S?@'+<QK2QF
M3XO^S<3)N3A%7HN;U<HQBXSHN^KY'RWV@CRI/V-_VT+)?LMA^T:%LX?DMU'Q
M&^)4`$8^Z!"NE,(AC^$,0.U>J^,N"I/FGPT^=ZO_`&3!O7UYU^1Y:X-XTIKD
MI\26A'1?[5C%IZ<CM]YS^I?L&_M0^(-:T/7?%GQ7\)>+[SP]<P7&FGQ+XM\<
M:NT"0W45XUM#+?>'I7MX))8E+K&5SUZBNBEQYPMAJ->A@\HQ&"AB(RC/V-##
M4TVXN/,U&JDVD]+G/4X#XHKUJ%?%YMA\7/#2C*'MJV)G9*2ERIRI-Q4FM;'W
MA^T%^R]X2_:-\/Z5)XD_XI7QYI%EY6F^)='*ZD++S?WT^DWJS1VIUO11=-(\
M886LJ,[/$T7G3)+\'P]Q1B^&L156%_VK`597G1J>YS6T52-G+V57ET;7-%K2
M2E9-?=\0\+X3B/#TGB?]DQ]&-H5J?O\`+?65.2:C[2G?5)\K3UBXW:?QQ;_L
M<?MD^'X4TCPQ^T>+?0[,>7I\"^.?B%I:10#A$33[?3IXK10H`$<<KJO0'%?9
M2XRX,Q$G6Q7#-Z\]9OZMA)Z]?><H.7JXIL^.AP;QGAHJCA>)5&A#2"^L8N%E
MVY>62CZ*32.M\&_LY_MQ^$O%&A^(9OC[I7B"UTK4K2[O="UOQSX[U'2]8L8I
MT>\TR\M;_P`.S0^5<VZR0^9Y>^/S/,C*NBL.3&<1\"XO"U\-'AZ>&G5A*,:M
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MGP19/;V,$C7>H7]TR2ZIK>J2HB7&J:I<HB"6Y=8XT541(XHXHXHD5$`K\WSC
M.,;G>-GC<;-.HURPA'2%*"ORTZ<=;15V]6W)MR;;9^CY1E&"R/!0P.!@XTXO
MFE*6LZDW:\YO2\G9+1))))))'A_Q3_92TGXD?M"?#+XRRS:=#IOAB)'\8Z1.
MDYN=>N]`D:\\(2VZ)$T,H6\D6*\,[IFUL((T#[CL]S*N*ZN6</9GDJC-U,2_
M]GJ)I1HQJKEQ">J:O%7I\J?ORDW8\/-.%*68\0Y9G+E"-+"K_:*;3YJLJ3YL
M.UHT[2=JG,U[D8I7/JGQ!X?T7Q5HFJ>&_$6FVNK:'K=E/IVJ:;>)OMKNSN4*
M2Q2`$%3@Y5T*NC*KHRNH8?*X?$5L'7I8G#5)4*]"2G3G%VE&2=TU^J>C6C33
M/JL1AZ.*H5<-B*4:U"M%PG"2O&49*S3_`,UJGJFF?E_KG_!/[XE>"?$%_JO[
M/'QIOO".FZ@[,=+U/5O$&@7]I$SR,EI)K'AJ.8:Q!&KXC:>T@<`?,7?+M^HT
M/$'+,;AZ='B+(XXNK3VG3A2J0D^LE3K6=-OJH3<;]$M#\PK^'^9X'$5*O#N=
MRP=*I]B<ZM*<5TBZE&ZJ)+9R@I=V]WE'_@FYXP\2Z3XDUKXB?&!]?^(U[91K
MH5TS:KJ6EPW\<\4I?7M9U=7U&_M7MUFMU6"UA,)F$H\X1^2VO_$2,%AJN%H9
M=DWU;+:<OWL?W<*C@TU:E3IVI0E>TKRE+FMR^[>YE_Q#?&8BEB:^8YQ]8S*<
M?W4OWDJ:FFG>K4J-U)QM>-HQCRWYO>M9_1?ACX4?M)^!_P!G?2O@KX/O?AEI
M/B2QM]8TE_'9\1>)66UT?5M1OK\S:3IZ^$A)!KRIJ$EN+B23RXO+$\:F4J(O
MG,3FW#6-XBJYWC*>-JX:<J=187V5%7J0A&-JD_;V=*\5)Q2O*_*VEO\`18;*
M>)<#P[2R7!U,%1Q-.-2G]:]K6?+3G.4KTX>PNJMIN*DW:/Q)-VMT_P"R;^RY
M9?L[^'M3NM9O+#7OB)XEDQKNNV2S-9VFFQ2;[71-)ENX(IS:^8/M-Q*\433S
M,@9=EK#CEXMXIGQ#B*4*$)X;+<*OW5*5E)S:M*I-1;CS6]V"3:A'9WE(ZN$^
M%H<.8>K*M.%?,<2_WM6*?+&"=XTZ;DE+EO[TY-)SD]5:,3E_C/\`L8VOQ"^+
M7A_XO>`?&\_PL\3VUS%=^([[2=,:ZN;^^L]GV/6M.$5]:I;:L\(:WN3*7BN$
M".Z%_.%UU9)QI++<IQ&3X_`1S7"M.-&%2?+&$9?%2G[LG*G?WH<MI0=[-*W+
MR9UP7',,VP^;Y?CGE.*BU*M.G#FE*<=(U8>]%1J6]V=[QFK<R;OS?2_ACX:Q
MZ/!`?$OBWQ=\0]1B$;->^+=0MS9^<@P9(?#^C6ECI47/(+VDTB_\]"<D_,XK
M,G5E+ZK@\/EM)WM'#P?-9]'5J2J57\II/L?387+51C'ZSB\1F%16]ZO-<MUU
M5*G&G27S@WYGI:J%`50%50`JJ``H'0`#@#%>8>GMHM$CQ^^^,_A_3?%'_"*7
M.EZS]ODUW3]`M9;>*TN()[O4->T;08Y',=UFWB5]5N;P^8`WV71;YL"6-87]
MBGDN(GA?K4*M-4U2G5DFY1:C"E4JM:QU;Y%#33GJ4U\+<EY$\YP]+%?594JB
MG[6%*+2BTY3JTZ2>DM%><IZ_8IS?Q)1?L->.>N%`!0`4`%`!0`4`-V+N#;5W
M#@-@;AUZ'&>Y_.B[6FR[!9=AU`!0!0&JZ7_:;:(-2L/[92R&I-I(O+?^TUTY
MIC;K?M8"3SULC<`Q"<Q["XV[MW%:>RJ^R5;V4_8\W(I\KY.>U^7FMR\UM>6]
M[:VL9^UI>U]A[2'ME'G]GS+GY+VYN6_-RWTYK6OI>YBMXY\$QP0W3^,/"T=K
M/'J$UO<-X@TE8)H=)D\G5989C=A)([.;Y+AE)$+?+(5/%;+`XWF<%@Z_-%P3
MBJ52Z=17IIKENG-:P7VEJKF+QV"C%2>,H1@U-INK32:@[3:?-:T'I-KX7O8U
MGUO1H;G2[*35M,CO-;2:71;1[^U2YU:.WA6YN)-+@:4/?I%;NLKM`L@5&#L0
MIS62H5N6K-49\E!I5)*$N6FV[)3=K0;>BYK7>BU-76HQE2@ZL(SK)NG'FBG-
M)7;@KWDDG=\M[+5Z%(^+/"J:-'XC;Q+H">'I9/*BUU]8T]-&DD^TM9[(]3:X
M%L[F[1X0%D),BE!\PQ5K"8KVSPRPU7ZQ%7=)4Y^T2MS7<+<R]U\VVVNQ#Q>%
M5%8CZS2CAV[*HZD%3OS<ME._+\7N[[Z;EJ\U[0]-N([34-9TJPNI+.[U&*VO
M-1L[6XDT_3X_-O[^.&>97>SMHOGFF`*1+R[**B&'KSBYTJ-2<(RC!RC"32G-
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M<X6T]Z,9-QUTU2U.IKE.H*`"@"AJ&JZ7I"6TFJ:E8:9'>7MMIMF^H7EO9)=:
MC>/Y=G86S7$B">]GDRL<";G<\*I-:4Z56JY*E3E4<(N<E"+ERPCK*3Y4[1BM
MY/1=69U*M*BHNK4C24Y*$7*2CS3EI&*NU>4GHHK5]$7ZS-`H`*`"@"(00*[.
ML,2N[B1W$:!W=0JJ[,!EG"JH!/.%`[4^:5DKNRT2OT_IBY8IMJ*3W>EM26D,
M*`"@`H`*`"@`H`*`"@`H`_-#Q==_$Z3XH?M4?&KP/XLT;PEIGPU\/:=X&0:Q
MX.D\37FN1^&_#O\`;NI:;HTYU&U&F2/X@G$6\)<J\EQ`S*!%AOTS!PRR.5<*
M9)CL)4Q=3,ZT\5^ZQ*H1I.O6]C"=5<D^?]U&]FX-13L_>/S3%RS/^U>*L[P.
M+IX.GEE&&%_>89UI550H^VG"D^>')>K*UTI)R:NM#S#PA\,;K5/#WB#PFUC,
M@^&7[%-U;F!K>3,/Q$^+@U3Q_>R`LGS7RVT@@;;E]P;/.!7J8O-%0KX?&0JI
M?VGQ)&2M+_F%R_DPL/\`MV[;CTL>9A,K=:AB,'*D_P#A,X;E'6/_`#%9ASXJ
M?3XK))]3M?!6K>*O$/P[G^.=Y875AXHU/P=X0_9S_9YT>_1X[FSU75X+#PUX
MA\9PPY*K<7?B*34;I9U"2)IWAV=&+1/D\..HX7"YA'(85(SPM+$8C.,WJ0=X
MRA3<ZU'#MK=4Z/+&VWMJZMJCMP-7%8G+Y9]*G*GBJF'H91E%.:M*,ZBA2K8A
M+I*=;FE?=4:+OHS%^/&AZ[XRT/5/A)\//`'B'Q9\'_V>/`&J:#=:CI&K:/H=
MI<?%:T\,-#::I?Q:I=PS>(;+PYIS7<\]KIR332ZAJ$H8-^[\S;(:]#`UZ6;Y
MAF%'!YQQ#BH58PG"I4E'`3K>_3BZ<6J,L3.T8RJ.,8T8*UDW;'/:%?&T*V49
M?E]7%91P]A9TG*$Z=.+Q\:/N5)*I*+K1PT;SE&FI2=:;W:5^<^*GCRZ\8:5X
M^^(2K=.N@?LK?##X=V>^VN@(_%'QLO;&]\0R#$1?[3!X=;4HI@BED2*12,L`
M>G*<!#!5,ORZ\5[?/,;C)QYHI.AED91HWUM:55Q<;]7H<V:XZ6,IYAF"4O\`
M9\CP6#A+E>E?,YQE6MI>\:2DI6V2=SM+:T^&EYXS\(^*O@7X(\0W/@7X4_"3
MQ]IWQ7\8?#SP?>>&KOQNFL^&+;0--T/1_P"T+/31XF\56UU]IUEI6$C*8@_F
MO)$%7CE+,XX+%X3/<?1ACLVS#"SP.'Q>(C6CAG"LZM2M4Y)5/84)1Y:-M$T[
M62=SLC#+'C<)BLBP%:6!RG+\5#'8C!X>5&6)52BJ5.C3YHTO;UXRYJU]6K7N
MW9&M^RY!X47XI^#_``WX33P9\3?#O@WP-K.H:+\3_#?@O6/`GBSP3)J)CLAX
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M3J%S;R36%MK&J75S%;NMT4:4;_<K9!E%&A3PF.P]#"6QN`PD:].,Z3DIWEB*
MRKU*\W6I58Q:C4E1I4X.2=.Z6GAT,_S>I7J8K`5Z^*O@L?BY4*DH5%%PM'#T
MG0I4(*A5I3DG*G&M5J32:J6;UZA_BMXETSP-=ZYX)^/7CKQOI>H7'PRT/XC^
M-M9\'V-WH'PSN/%.HE_&'BKPOKD6BVT$#:;IH>WFT1K2]CTXW=O--,LP1*Y5
ME6&J8Z%#&Y!A<#5I+&U<'AJ>(E"KC%0A_L]"O2=64FJD[2C64J<J]I1@G%W.
MIYKB:6!G7P.?8K&4JCP5+%XFIAXRI8)UY_[17H553C%.G"\947&I&CS1E)J6
MA-K7Q)U&Q3P>OA[XA>,/BAX)TO7/BK\3X?$'C;PCI_VU]`^%G@9I]-MM,UA]
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M\5?BLO@CQQ<V?QOM)M`N;KP'I&G^/-4U#4_$.D6'BJ]EN;_Q)8P_$.T^%NF:
M?X3TC4-(@\AIY;+4(=&NVMX'FADNE8;5<JRGZ[@8SR.4<1%8NI/"TXPHU)4(
MI1H2>$EC:M2O4I5'S<JG3EB:?-))J+,J6:9LL%CI4\[BZ$I86G#%3E.M3C7D
MY2KQ6+C@J5.A3JTUR\SA4CAJCC%R3DC[>_9E\1:QXJ^%5AKFLWWBJ_EN]9UQ
M;.7Q=-IVH7Z:?;7S6ULEAK^FZ=8)XHT,F*22TU>6SMY;F.4%DVHI/Q'$^&HX
M/-9T*%/#TU"E1<EAU.$.>4%*7/2G.HZ%75*K14Y1A)-)[H^VX8Q-;%95"O6G
M7FY5:RB\0X2GR1FXQY*L(4U7I:-TJSA&4XM-KJ?0-?/'T`4`%`!0`4`%`!0`
I4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
